Targeting prostaglandin E EP receptors to inhibit metastasis.
about
Epigenetic regulations of inflammatory cyclooxygenase-derived prostanoids: molecular basis and pathophysiological consequencesMica Nanoparticle, STB-HO Eliminates the Human Breast Carcinoma Cells by Regulating the Interaction of Tumor with its Immune MicroenvironmentInflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancerG-protein coupled receptor expression patterns delineate medulloblastoma subgroupsProstaglandin E2/EP1 signaling pathway enhances intercellular adhesion molecule 1 (ICAM-1) expression and cell motility in oral cancer cells.Cyclooxygenase-2 enhances alpha2beta1 integrin expression and cell migration via EP1 dependent signaling pathway in human chondrosarcoma cells.Cyclooxygenase-deficient pancreatic cancer cells use exogenous sources of prostaglandins.Prostanoid receptor antagonists: development strategies and therapeutic applicationsProstaglandin E2-induced colonic secretion in patients with and without colorectal neoplasiaLymphovascular and neural regulation of metastasis: shared tumour signalling pathways and novel therapeutic approaches.Acute inflammation reveals GABAA receptor-mediated nociception in mouse dorsal root ganglion neurons via PGE2 receptor 4 signaling.COX-2 and prostaglandin EP3/EP4 signaling regulate the tumor stromal proangiogenic microenvironment via CXCL12-CXCR4 chemokine systems.Piracy of prostaglandin E2/EP receptor-mediated signaling by Kaposi's sarcoma-associated herpes virus (HHV-8) for latency gene expression: strategy of a successful pathogen.Prostaglandin E receptor EP1 suppresses breast cancer metastasis and is linked to survival differences and cancer disparities.Exposure to extremely low-frequency electromagnetic fields modulates Na+ currents in rat cerebellar granule cells through increase of AA/PGE2 and EP receptor-mediated cAMP/PKA pathway.Prostaglandin receptors EP1-4 as a potential marker for clinical outcome in urothelial bladder cancer.Regulation of circulating endocannabinoids associated with cancer and metastases in mice and humans.cAMP/PKA Pathways and S56 Phosphorylation Are Involved in AA/PGE2-Induced Increases in rNaV1.4 CurrentNovel link between prostaglandin E2 (PGE2) and cholinergic signaling in lung cancer: The role of c-Jun in PGE2-induced α7 nicotinic acetylcholine receptor expression and tumor cell proliferationExposure to 50 Hz magnetic field modulates GABAA currents in cerebellar granule neurons through an EP receptor-mediated PKC pathwayProstanoid EP₁ receptors mediate up-regulation of the orphan nuclear receptor Nurr1 by cAMP-independent activation of protein kinase A, CREB and NF-κB.Molecular inhibition of prostaglandin E2 with GW627368X: Therapeutic potential and preclinical safety assessment in mouse sarcoma model.The connection between lymphangiogenic signalling and prostaglandin biology: a missing link in the metastatic pathway.Association of EP2 receptor and SLC19A3 in regulating breast cancer metastasis.A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE2-mediated immunosuppression and inhibits breast cancer metastasis.TGF-β effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K/AKT/mTOR pathway.GW627368X inhibits proliferation and induces apoptosis in cervical cancer by interfering with EP4/EGFR interactive signalingProstaglandin E2 EP receptors as therapeutic targets in breast cancer.Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-beta through a PGE2-dependent mechanisms.Regulation of the prostaglandin pathway during development of invasive bladder cancer in miceTumor-growth-promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targetsRole of the prostaglandin pathway and the use of NSAIDs in genitourinary malignancies.Transgenic insulin-like growth factor-1 stimulates activation of COX-2 signaling in mammary glands.Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties.Multiple drug resistance-associated protein (MRP4) exports prostaglandin E2 (PGE2) and contributes to metastasis in basal/triple negative breast cancer.Cyclooxygenase-2 expression in animal cancers.Novel prostaglandin receptor modulators: a patent review (2002 - 2012) - part I: non-EP receptor modulators.Novel prostaglandin receptor modulators--part II: EP receptor modulators; a patent review (2002 - 2012).The obesity-inflammation-eicosanoid axis in breast cancer.The role of prostaglandin E2 in renal cell cancer development: future implications for prognosis and therapy.
P2860
Q26862642-FA9ACF20-7319-405C-A849-BB608AFA9187Q27304695-CB70EFA5-275B-4527-B8FF-56DFC9F97F31Q28218639-ABDA345A-68EC-49ED-A31F-F8524C07B853Q28302285-9221469E-ED25-4920-ABDD-A0B27257A281Q30430640-1FB8BF73-8968-4A32-8D1B-B58E2ECF9F14Q30436782-7FA57098-500B-4EF2-BF58-5CEB28B88C5BQ30494961-E8C60AC9-07C6-41F3-8FF3-D19982B55B9DQ33485483-A33274CF-D81B-49AF-8F5C-230B9502155CQ33526510-7217D1DE-8A10-48FE-BB17-62A989BD7C1CQ33555154-7EB65C5E-93AD-440E-8F73-7B8C9EF20E32Q33612311-6B628ACC-9725-46DC-A83D-C42F8BD6AC93Q33703810-B3FB83DC-A2B0-45C8-9E65-324AC32232ACQ33820704-E9C6C389-C013-4B60-B56F-45D4400E5344Q34279863-47D8811D-3156-45FA-81F3-BB0C62BA2CBBQ34562987-DB415D03-6666-47DB-A70E-ED8203335AC2Q34705013-F9B1C4B0-0398-464F-8793-0EE85045F78CQ34781231-5F323C07-F10A-42C1-949D-7B0A31CDC3A7Q35814531-D66AA22F-4919-4DA7-B8F2-A4E35E44961DQ35879417-0452AF2B-202E-4E68-87E1-42C00E4434E3Q36125386-DBE6BF13-20F9-450F-B6A5-66E838130DCAQ36158964-700F230D-FA5E-40F8-92D1-326DA30C3022Q36215333-7C29AB9C-16A1-4604-A675-692C879B2AA5Q36339264-60D6D98E-4FFC-4BAE-855A-E8E5C1D67B76Q36420170-8116FA11-E3DD-4D22-AA8C-1D5DDD2DC6F8Q36643655-134D01AD-3096-423B-97C9-8FBAC949F648Q36771000-5EFC8F64-B934-435D-8506-00CEE6C3B99CQ36775030-070F46FF-DEDF-4EA2-B95E-C6217A5F9396Q36806255-20411D82-1DDE-4091-B118-5C915265F634Q36959011-BE1CA932-8BF8-448C-8E22-044B152BE3A9Q37041680-F095B723-8EF9-4611-A207-69924363F8CDQ37152015-147E70DC-C285-44BB-86F9-8ED9AC201C19Q37202773-1F82A100-EB68-4114-B632-504E20E725A4Q37215586-B43E8E8C-C0B6-4240-A3CA-6E39AD2091DDQ37470737-88219871-995A-4673-BCE0-8BD3921C30D6Q37701635-78899F36-F67A-48B6-BC87-156AB59FB30FQ37793667-8FBA7AB3-D25A-4FF6-8955-48F5FAEED7DEQ38059757-B6D4810B-6706-4E50-A904-6B4A598E7ACDQ38071643-DFA18FD9-9CF5-43FE-AF06-DB75A0F3FB44Q38156366-D2295675-FE96-4BC3-BAA4-671F019721FEQ38282450-2C5FB0CD-7FF8-44F2-AD26-239014BF1054
P2860
Targeting prostaglandin E EP receptors to inhibit metastasis.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Targeting prostaglandin E EP receptors to inhibit metastasis.
@ast
Targeting prostaglandin E EP receptors to inhibit metastasis.
@en
type
label
Targeting prostaglandin E EP receptors to inhibit metastasis.
@ast
Targeting prostaglandin E EP receptors to inhibit metastasis.
@en
prefLabel
Targeting prostaglandin E EP receptors to inhibit metastasis.
@ast
Targeting prostaglandin E EP receptors to inhibit metastasis.
@en
P2093
P1433
P1476
Targeting prostaglandin E EP receptors to inhibit metastasis.
@en
P2093
Amy M Fulton
Namita Kundu
Xinrong Ma
P304
P356
10.1158/0008-5472.CAN-06-2067
P407
P577
2006-10-01T00:00:00Z